Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Context The US Food and Drug Administration recently recommended that CYP2C19
genotyping be considered prior to prescribing clopidogrel, but the American Heart …

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …

Background It has been suggested that clopidogrel may be less effective in reducing the rate
of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 …

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and
pharmacodynamcis of clopidogrel. Twenty‐four subjects were divided into three groups on …

Background Clopidogrel requires transformation into an active metabolite by cytochrome P-
450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …

Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

We systematically investigated how 11 overlapping meta-analyses on the association
between CYP2C19 loss-of-function alleles and clinical efficacy of clopidogrel could yield …

Objectives: The aim of this study was to assess the association between the loss-of-function
cytochrome P450 2C19 (CYP2C19)* 2 variant (10 studies, 11,959 patients) or the use of …

Loss-of-function (LOF) variants of cytochrome P450 2C19 (CYP2C19) have been
hypothesized to be associated with lesser degrees of platelet inhibition and increased risk …